Insider Transactions and Merger Agreement for Day One Biopharmaceuticals

This filing details insider transactions for Day One Biopharmaceuticals, Inc. (DAWN) on April 23, 2026, coinciding with the company's merger with a subsidiary of Servier Pharmaceuticals LLC. Director Josey John A. reported the disposition of 72,292 shares of Common Stock. Additionally, several stock options and Restricted Stock Units (RSUs) were disposed of. These options and RSUs were fully vested immediately prior to the merger and were canceled in exchange for cash, with the amount based on the merger consideration of $21.50 per share, less any applicable exercise price for options. The merger agreement, dated March 6, 2026, outlined the terms of the acquisition, where Day One Biopharmaceuticals survived as a wholly-owned subsidiary of Servier.